Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 24, 2013

Primary Completion Date

April 24, 2015

Study Completion Date

June 11, 2018

Conditions
Colorectal Neoplasms
Interventions
DRUG

Regorafenib (Stivarga, BAY73- 4506)

160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

Trial Locations (11)

27010

Gaziantep

34093

Istanbul

34899

Istanbul

35100

Izmir

06100

Ankara

06500

Ankara

Unknown

Antalya

Bursa

Kayseri

Samsun

01330

Balcali/Adana

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY